FDA reviewers have identified high rates of ocular toxicity as GSK looks to place its blood cancer drug back on the market.

With GSK kicking its research and development engine into high gear in recent years, a shuffling of the scientific priorities ...

GSK PLC closed 16.45% short of its 52-week high of £16.79, which the company reached on September 9th.

British drugmaker GSK said on Monday it had submitted an application to the U.S. Food and Drug Administration to extend the ...

The U.S. Food and Drug Administration's staff reviewers on Tuesday raised safety concerns that GSK's blood cancer drug ...

In briefing documents released ahead of an Advisory Committee meeting this week, FDA staffers cited safety risks related to a ...

GSK has been enjoying regulatory momentum in recent months as it works to bring its antibody-drug conjugate (ADC) Blenrep ...

ViiV Healthcare, the HIV-focused joint venture majority owned by GSK , said on Monday it has expanded its licensing deal with ...

GSK's blood cancer drug, Blenrep, is under the U.S. Food and Drug Administration (USFDA) spotlight, as staff reviewers raised ...

No investor will be happy with their GSK shares as the FTSE 100 pharmaceutical giant has had a dismal decade. Will the next ...

GSK specialty medicines grew YoY in Q1 2025, and it is now the main profit engine, offsetting the weakness in their vaccine ...

GSK PLC closed 16.09% below its 52-week high of £16.79, which the company achieved on September 9th.